Our Expertise Helps Patients in Need

Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.

LEADERSHIP

Calliditas is led by an experienced and dedicated management team. The team has a strong knowledge of the pharmaceutical industry, as well as commercial and general management expertise. Our broader leadership team has experience from companies such as GlaxoSmithKline, Pfizer, Novo Nordisk, Regeneron, BMS and AstraZeneca.

MANAGEMENT TEAM

Renée Aguiar-Lucander

Chief Executive Officer

Renée Aguiar-Lucander

Chief Executive Officer

Born 1962. CEO since 2017.

Education:
BA in Finance from Stockholm School of Economics. MBA from INSEAD.

Experience:
Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services.

Other current assignments: –

Holdings in the Company:
Renée Aguiar-Lucander holds 643,000 shares in the Company and 591,000 options.

Frank Bringstrup

Vice President Regulatory Affairs

Frank Bringstrup

Vice President Regulatory Affairs

Born 1959. VP Regulatory Affairs since 2019.

Education:
Medical education from the University of Copenhagen. He has a diploma in Managing Medical Product Innovation (MMPI) from the Copenhagen School of Economics, a diploma in business administration from Warwick University, and a post graduate specialist course in public health science from the National Board of Health, Denmark.

Experience:
Frank Bringstrup has over 17 years of experience in the pharmaceutical industry within regulatory affairs and health authority interactions. Prior to joining Calliditas, he worked in various positions at Novo Nordisk A / S. He started his professional career first as a clinic doctor and then Frederiksborg County Medical Advisor.

Holding in the Company:
Frank Bringstrup holds 8,000 shares in the Company and 95,000 options.

Sandra Frithiof

Head of Human Resources

Sandra Frithiof

Head of Human Resources

Born 1975. Head of HR since 2020.

Education:
Bachelor’s Degree in Human Resource Management from Örebro University, Sweden.

Experience:
Sandra Frithiof has more than 23 years of HR experience in different industries. Before joining Calliditas Sandra worked as Head of HR and COO at Ramberg Advokater. Previous HR positions also include Karolinska University Hospital, UTC, CGI and Manpower Group.

Holdings in the Company:
Sandra Frithiof holds 75,000 options.

Fredrik Johansson

Chief Financial Officer

Fredrik Johansson

Chief Financial Officer

Born 1977. CFO since 2017.

Education:
Studies in Business Law at Jönköping International Business School. Studies in Business and American law, Economics and Finance at Georgia State University, University of South Carolina and Lund University.

Experience:
Fredrik Johansson has extensive experience in executive positions, primarily within telecom and software. Previously, he was CFO and COO at Birdstep Technology/ Techstep ASA, listed on the Oslo Stock Exchange, where he, among other things, was in charge of the acquisition and reversed listing of Teki Solutions. Previous CFO positions also include Phone Family, Teligent Telecom and Wayfinder Systems.

Holdings in the Company:
Fredrik Johansson holds 42,750 shares in the Company and 205,000 options.

Richard Philipson

Chief Medical Officer

Richard Philipson

Chief Medical Officer

Born 1964. Chief Medical Officer since 2020.

Education:
BSc in Biomedical Sciences at London University and MB MS, Middlesex Hospital Medical School. Fellow of the Royal College of Physicians and Fellow of the Faculty of Pharmaceutical Medicine.

Experience:
Dr. Richard Philipson is a physician with 24 years of experience in the pharmaceutical industry from both large pharmaceutical companies and smaller biotechs. He has extensive experience in rare diseases, having brought several products from early development to the market. Prior to joining Calliditas, Richard worked as CMO with the UK-based biotech company Trizell where he led the Adstiladrin® phase 3 clinical program and Biologics License Application in non-muscle invasive bladder cancer, submitted to the FDA in September 2019. Before Trizell, he worked for Takeda as an Executive Medical Director and spent 16 years at GlaxoSmithKline, where he held a number of senior positions, including Disease Area Head and Acting Chief Medical Officer for the Rare Diseases Unit.

Before joining the industry, Richard worked as a physician in several clinical positions with various patient populations, including patients with IgA nephropathy.

Holdings in the Company: 125,000 options.

Jonathan Schur

Group General Counsel

Jonathan Schur

Group General Counsel

Born 1953. Group General Counsel since 2020.

Education:
Bachelor’s Degree in 1975 from Harvard University, J.D from Harvard Law School.

Experience:
Jonathan Schur has over 40 years of experience as a lawyer, is a member of the New York Bar, and a former member of the Paris Bar. Prior to joining Calliditas, Mr. Schur was a Partner in the Life Sciences practice group at Goodwin Procter LLP, and before that a partner and co-managing partner of the Paris Office of Dechert LLP.

Holdings in the Company:
Jonathan Schur holds 165,000 options.

Andrew Udell

President, North America

Andrew Udell

President, North America

Born 1970. Head of North America, Commercial since 2020.

Education:
BSc from Lehigh University. MBA from the University of Connecticut

Experience:
Andrew Udell has more than 20 years of commercial experience in the pharmaceutical industry. Before joining Calliditas, Andrew worked as Vice President of North America Commercial at NeuroDerm. Andrew began his career in the pharmaceutical industry at Purdue Pharma and held several sales and marketing positions, including being responsible for the company’s brands and leading a multi-functional team for a multi-billion pain medication franchise.

Holding in the Company:
Andrew Udell holds 26,000 shares in the company and 235,000 options.

Shareholding in the Company as of December 31, 2022.

For more information on the warrants, see section Remuneration.

BOARD OF DIRECTORS

Elmar Schnee

Chairman

Elmar Schnee

Chairman

Born 1959. Board member since 2019.

Education:
Master’s degree in marketing and management from SIB.

Board Committees:
Chairman of the Remuneration Committee.

Experience:
Elmar Schnee was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.

Other current assignments:
Chairman of the board of directors of ProCom Rx SA, Moleac Pte Lts and Noorik Biopharmaceuticals AG as well as a member of the board of directors of Kuste Biopharma, Mindmaze SA and Damian Pharma AG.

Holdings in the Company:
Elmar Schnee holds 10,000 shares in the company, 14,063 share awards in LTIP 2020, 10,624 share awards in LTIP 2021 and 13,926 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Chairman of the Board

Chair of the Remuneration Committee

Member of the Board of Directors

Member of the Remuneration Committee

Member of the Nomination Committee

Elisabeth Björk

Non-executive Director

Elisabeth Björk

Non-executive Director

Born 1961. Board member since 2022.

Education:
MD degree, Karolinska Institute, Stockholm and Associate Professor, Medicine, Uppsala University

Board Committees:
Member of the Remuneration Committee.

Experience:
Elisabeth Björk is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. Elisabeth Björk is the Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca leading the global development of medicines within this area. Throughout her career at AstraZeneca, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan) and commercial strategy/implementation.

Other current assignments:
Board member in Rocket Pharmaceuticals, Pharvaris NV, Chalmers University of Technology, Chalmers Ventures.

Holdings in the Company:
Elisabeth Björk holds 5,356 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors

Member of the Remuneration Committee

Hilde Furberg

Non-executive Director

Hilde Furberg

Non-executive Director

Born 1958. Board member since 2014.

Education:
Master of Science in Engineering from Oslo University, Norway.

Board Committees:
Member of the Audit Committee.

Experience: Hilde Furberg is an independent consultant and professional Board member. She has extensive experience of leadership from her 35 years in sales, marketing, strategy and management in Pharma / Biotech. Her experience is in various fields of rare diseases, which she gained working in small companies and large global corporations. Hilde has worked in companies such as Genzyme and Baxter, she was most recently SVP and General Manger / European Head of Rare Diseases at Sanofi Genzyme. In addition to working for Genzyme / Sanofi Genzyme, Hilde has since 2005 worked as non-executive director and Board member of Probi, Pronova, Clavis, Bergenbio and Algeta.

Other current assignments:
She is currently an industrial advisor to Investinor and Board member of PCI Biotech, OncoZenge, Herantis Pharma, Sedana Medical and Bio-Me.

Holdings in the company:
Hilde Furberg holds 44,750 shares in the company, 4,327 share awards in board LTIP 2020, 4,086 share awards in LTIP 2021 and 5,356 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors

Member of the Audit Committee

Molly Henderson

Non-executive Director

Molly Henderson

Non-executive Director

Born 1970. Board member since 2020.

Education:
M.B.A. and B.S. degree from the State University of New York at Buffalo.

Board Committees:
Chairman and member of the Audit Committee.

Experience:
Molly Henderson has served as the CFO of several listed life science companies for over 17 years. Currently, she is the CFO of Phathom Pharmaceutical, Inc. She was previously the CFO of Urogen and Executive Vice President of Advaxis, Inc, the CFO of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) and before that the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Molly has also advised start-up companies in Switzerland, and was a Manager in the audit division of PricewaterhouseCoopers LLP.

Other current assignments:
CFO of UroGen Pharma, Inc.

Holdings in the Company:
Molly Henderson holds 100 shares in the company and 4,327 share awards in board LTIP 2020, 4,086 share awards in LTIP 2021 and 5,356 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors

Member of the Audit Committee

Diane Parks

Non-executive Director

Diane Parks

Non-executive Director

Born 1952. Board member since 2019.

Education:
Master’s degree from Kansas State University and an MBA from Georgia State University.

Board Committees:
Member of the Remuneration Committee.

Experience:
Diane Parks is a senior executive with deep sales and marketing experience from the US, where she has held positions such as Head of US Commercial for Kite Pharma, VP of Sales for Amgen and Head of Global Marketing at Pharmacyclics.

Other current assignments:
Board member in CTI BioPharma, TriSalus Life Sciences, Kura Oncology, Soligenix and Celularity.

Holdings in the Company:
Diane Parks holds 4,327 share awards in board LTIP 2020, 4,086 share awards in LTIP 2021 and 5,356 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Member of the Board of Directors

Member of the Remuneration Committee

Henrik Stenqvist

Non-executive Director

Henrik Stenqvist

Non-executive Director

Born 1967. Board member since 2022.

Education:
Degree in Finance and Business Administration, University of Linköping

Board Committees:
Chairman of the Audit Committee.

Experience:
Henrik Stenqvist has served as CFO of several listed life science companies and currently, he is the CFO of SOBI. Previous positions include CFO at Recipharm, CFO at Meda, Regional Finance Director at AstraZeneca, Finance Director at Astra Export & Trading and Board member of MedCap AB.

Other current assignments:
Board member in Midsona AB.

Holdings in the company:
Henrik Stenqvist holds 10,000 shares in Calliditas and 5,356 share awards in LTIP 2022.

Independent in relation to the Company and its management and in relation to major shareholders.

Chairman of the Audit Committee

Member of the Board of Directors

Shareholding in the Company as of June 1, 2022.* For more information on the incentive programs, see section Remuneration.

OUR HISTORY

Since our founding in 2004, Calliditas has worked to deliver life-changing medications to patients in need.

2022

COMMERCIAL LAUNCH OF TARPEYO in the US

TARPEYO^® (budesonide) delayed release capsules became commercially available in the United States

NEFECON IN EUROPE, CHINA AND OTHER REGIONS

Following a positive opinion issued by the Committee for Medicinal Product for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission (EC) approved KINPEYGO in Europe, granting Calliditas a conditional marketing authorization for adults with primary IgA nephropathy at risk of rapid disease progression

Chinese Regulatory authority National Medical Products Administration (NMPA) accepted Everest Medicines’ New Drug Application for NEFECON

ADVANCING PIPELINE WITH SETANAXIB

The first patient was randomized in pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis (PBC)

The first patient was randomized in the Phase 2 Proof of Concept study in patients with Head and Neck cancer

2021

TARPEYO RECEIVES FDA APPROVAL IN IgA NEPHROPATHY

On December 15, 2021, the FDA granted Calliditas accelerated approval of TARPEYO to reduce proteinuria in patients with IgA nephropathy. TARPEYO became the first and only approved treatment for this indication

Submitted a New Drug Application to the United States (US) FDA and a Marketing Authorization Application to the European Medicines Agency for patients with primary IgA nephropathy

Announced full enrollment of the Phase 3 NeflgArd trial

EUROPEAN COMMERCIAL PARTNERSHIP

Partnered with STADA Arzneimittel AG to register and commercialize a specialty therapy for IgA Nephropathy in Europe

GENKYOTEX ACQUISITION

Completed acquisition of Genkyotex, which became a wholly owned subsidiary of Calliditas and was delisted from the Euronext stock exchanges

SECURING FINANCING

Resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million

Secured a USD 75 million term loan facility from Kreos Capital

2020

SUCCESSFUL TOPLINE PHASE 2 DATA OF NEFECON

Announced positive topline results from the pivotal Phase 3 NeflgArd trial

US INITIAL PUBLIC OFFERING (IPO)

Listed on the NASDAQ Global Select Market, raising approximately USD 90 million

ACQUISITION OF GENKYOTEX

Acquired a controlling interest in Genkyotex SA

2019

CALLIDITAS ENTERS INTO GLOBAL PARTNERSHIPS

Calliditas and Everest Medicines entered into a licensing agreement to develop and commercialize Calliditas’ leading product candidate in Greater China and Singapore

ADVANCING THE PIPELINE

Finished recruitment for the pivotal Phase 3 clinical trial NeflgArd Part A
Exclusively in-licensed Budenofalk 3 mg oral capsules for the US market from the German pharmaceutical company. Dr. Falk Pharma GmbH

CALLIDITAS ESTABLISHED A US PRESENCE

Appointment of VP Commercial, North America

2018

FIRST PATIENT ENROLLED IN PIVOTAL PHASE 3 STUDY

First patient enrolled in pivotal clinical phase 3 study NefIgArd with lead candidate NEFECON

LISTING ON NASDAQ STOCKHOLM

Listed on NASDAQ Stockholm’s main list, raising approximately SEK 739 million

2017

INTRODUCING CALLIDITAS THERAPEUTICS

Pharmalink is renamed Calliditas Therapeutics

ADVANCING CLINICAL TRIALS

Positive results of Phase 2b Clinical Trial of Nefecon in Primary IgA Nephropathy published in The Lancet

Use of proteinuria as a surrogate marker and design of Phase 3 study accepted by the FDA

2016

ORPHAN DRUG DESIGNATION IN EUROPE

Obtained orphan drug designation from the EMA for lead product candidate NEFECON in Europe

PUBLICATION ON PROTEINURIA AS A SURROGATE ENDPOINT

Tufts Medical Center publishes the meta-analysis study related to changes of proteinuria as a surrogate endpoint in IgA Nephropathy in American Journal of Kidney Disease

2015

COLLABORATION WITH KIDNEY HEALTH INITIATIVE

Invited to work with the Kidney Health Initiative (American Society of Nephrology) to identify surrogate endpoints in IgA Nephropathy

ADVANCING CLINICAL PROGRAM

Announced positive initial results from Phase 2B NEFIGAN trial, which met its primary endpoint in a planned interim analysis

2014

Global Patents Awarded

Core patents for lead product candidate were granted in the US, Europe, China and Hong Kong

2012

Phase 2b Trial Launches

Owners, including Industrifonden and Bengt Julander, financed the launch of the pivotal Phase 2b NEFIGAN trial

2011

GAINS EXCLUSIVE RIGHTS TO FORMULATION TECHNOLOGY

Pharmalink gained exclusive rights to the formulation technology, TARGIT^®, for developing and manufacturing lead product candidate under a 2011 agreement with Archimedes Development Ltd

2010

OBTAINED ORPHAN DRUG DESIGNATION

Pharmalink obtained orphan drug designation from the FDA for lead product candidate in the United States

2009

POSITIVE PHASE 2 STUDY COMPLETED

The Phase 2a study with lead product candidate was completed with positive results

2008

Lead Product Development

Identified the company’s lead product candidate

2004

Company Founded

Calliditas was founded in 2004 under the name Pharmalink AB and was registered with the Swedish Companies Registration Office on April 15, 2004